1st Quarter - Report
THORN RUN PARTNERS for BIOGEN
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Legislation that would alter payment policies under Medicare Part B for drugs and biologics. Issues pertaining to Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY PALMQUIST | Legislative Director: Rep. Dennis Cardoza, Rep. Bob Clement, Rep. Ken Bentsen |
| BEAU SCHUYLER | Legislative Director - Cong. Tanner, Legislative Director - Cong. McIntyre |
Health Issues HCR
Issues regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care. Issues regarding drug pricing as pay-fors.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY PALMQUIST | Legislative Director: Rep. Dennis Cardoza, Rep. Bob Clement, Rep. Ken Bentsen |
| BEAU SCHUYLER | Legislative Director - Cong. Tanner, Legislative Director - Cong. McIntyre |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.